, 2022-08-15 00:42:47,
VolitionRx (NYSE:VNRX – Get Rating) and Myriad Genetics (NASDAQ:MYGN – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.
Insider & Institutional Ownership
11.1% of VolitionRx shares are held by institutional investors. Comparatively, 97.4% of Myriad Genetics shares are held by institutional investors. 16.0% of VolitionRx shares are held by insiders. Comparatively, 1.8% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares VolitionRx and Myriad Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for VolitionRx and Myriad Genetics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Myriad Genetics has a consensus target price of $28.33, suggesting a potential upside of 2.62%. Given Myriad Genetics’ higher probable upside, analysts plainly believe Myriad Genetics is more favorable than VolitionRx.
Volatility and Risk
VolitionRx has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500.
Earnings & Valuation
This table compares VolitionRx and Myriad Genetics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Myriad Genetics||$690.60 million||3.22||-$27.20 million||($0.24)||-115.04|
VolitionRx has higher earnings, but lower revenue than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.
Myriad Genetics beats VolitionRx on 8 of the 12 factors compared between the two…
To read the original article, go to Click here